Mae Zakhour, MD, associate fellowship program director, Gynecologic Oncology fellowship, UCLA, UCLA Health, discusses the utilization of tisotumab vedotin-tftv (Tivdak) in cervical cancer.

Tisotumab vedotin is an intriguing new antibody-drug conjugate (ADC) that recently was added to the National Comprehensive Cancer Network guidelines for the treatment of cervical cancer, Zakhour says. This ADC is expected to become a viable option for patients with recurrent metastatic cervical cancer, where not many therapeutic options are available, based on clinical trial data over the past year, Zakhour explains.

Additional research is still being conducted for the use of tisotumab vedotin for these patients, and more needs to be learned regarding its toxicities, including some of the ocular adverse effects, Zakhour adds. With appropriate management of associated toxicities, the ADC may be utilized more often in the future, Zakhour concludes.

Videos

Mae Zakhour, MD, discusses the utilization of tisotumab vedotin-tftv in cervical cancer.


Dr. Zakhour on the Utilization of Tisotumab Vedotin in Cervical Cancer

Mae Zakhour, MD, a gynecologic oncologist and associate fellowship program director for the Gynecologic Oncology Fellowship at the University of California, Los Angeles Health, discusses clinical trials that evaluated frontline maintenance PARP inhibitors in patients with ovarian cancer.

The phase 3 SOLO-1 trial was the first to examine the use of the PARP inhibitor olaparib (Lynparza) as a maintenance treatment in approximately 400 patients, according to Zakhour. Patients enrolled to the study were required to have either a confirmed or suspected 

 mutation. The risk of progression or death was 70% lower in participants who received olaparib compared with those who received placebo, says Zakhour. A clear delineation could be seen with regard to progression-free survival (PFS) curves, although no statistically significant improvement in overall survival was observed at 3 years.

Additionally, the phase 3 PAOLA-1 trial examined the use of bevacizumab (Avastin) plus olaparib as frontline maintenance treatment in about 800 patients with advanced ovarian cancer, Zakhour adds. Patients were randomized 2:1 to receive either olaparib plus bevacizumab or placebo; notably, they were stratified based on homologous recombination deficiency (HRD) status. Data indicated a statistically significant difference in PFS in the intent-to-treat cohort with the doublet, particularly among those with HRD positivity, Zakhour concludes.

Mae Zakhour, MD, discusses clinical trials that evaluated frontline maintenance PARP inhibitors in patients with ovarian cancer.

Mae Zakhour, MD

Articles

Dr. Zakhour on the Utilization of Tisotumab Vedotin in Cervical Cancer

Dr. Zakhour on Clinical Trials Examining Frontline Maintenance PARP Inhibitors in Ovarian Cancer